JP Morgan Chase’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

JP Morgan Chase’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$42K	–	7586
2023 Q1	$42K	Buy	+10,000	New	+$51.9K	﹤0.01%	5771
2022 Q3	–	Sell	-63,000	Closed	-$376K	–	7196
2022 Q2	$376K	Buy	+63,000	New	+$323K	﹤0.01%	4732

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

JP Morgan Chase's CTIC Position: Q2 2023 in Review

JP Morgan Chase sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,124,714 shares — an estimated $4.72M sold.

JP Morgan Chase first reported a position in CTIC in Q2 2013 and held it in 35 quarters. The position peaked at $7.13M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

JP Morgan Chase reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
JP Morgan Chase sold 1,124,714 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $4.72M.
JP Morgan Chase first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 35 quarters.
JP Morgan Chase's CTI BioPharma Corp. (DE) Common Stock position peaked at $7.13M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.